border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your news release is automatically posted to your site once it hits the wire.
  • Saves you the time and cost of getting the news posted by a webmaster.
  • Automatically emails releases to your databases.


  • Product Description
  • Choose automatic or manual mode.
  • Automatic extraction of news from the wire, uploaded to your site.
  • Tied in with the email database to automatically send the release to your list(s).



  • 10/27/2009 10:34:09 AM ETNews Release Index 

    Oncolytics® Biotech Inc. Announces Issuance of 33rd U.S. Patent
     
    CALGARY, AB --- October 27, 2009 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”) today announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

    “This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN® in combination with a range of chemotherapeutic agents,” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. “Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers.”

    About Oncolytics Biotech Inc.
    Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

    This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company’s belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company’s expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company’s business and technologies, involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

    FOR FURTHER INFORMATION PLEASE CONTACT:

    The Equicom Group
    Nick Hurst
    300 5th Ave SW, 10th Floor
    Calgary, Alberta T2P 3C4
    Tel: 403.218.2835
    Fax: 403.237.6916
    nhurst@equicomgroup.com

    The Investor Relations Group
    Erika Moran
    11 Stone St, 3rd Floor
    New York, NY 10004
    Tel: 212.825.3210
    Fax: 212.825.3229
    emoran@investorrelationsgroup.com

    -30-

    News Release Index





    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol T.ONC
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer